NCT03574415 is a Phase 1 clinical trial of DWP14012 in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD..

Who is sponsoring NCT03574415?

NCT03574415 is sponsored by Daewoong Pharmaceutical Co. LTD..

What drugs are being tested in NCT03574415?

Interventions in NCT03574415: DWP14012, Placebo.

What condition does NCT03574415 study?

NCT03574415 studies Healthy Volunteers.

Is NCT03574415 still recruiting?

NCT03574415 is currently completed. Last updated 27 June 2019.

Last reviewed 2019-06-27 · How we verify

NCT03574415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean

Completed Phase 1 Last updated 27 June 2019

What this trial tests

Phase 1 trial testing DWP14012 in Healthy Volunteers in 80 participants. Completed in 23 January 2019.

Timeline

1 November 2018

Primary endpoint
18 January 2019

23 January 2019

Quick facts

Lead sponsor	Daewoong Pharmaceutical Co. LTD.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	80
Start date	1 November 2018
Primary completion	18 January 2019
Estimated completion	23 January 2019
Sites	1 location across South Korea

Drugs / interventions tested

DWP14012 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

Adults 19 to 50, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and tolerability of single and multiple ascending oral doses of DWP14012 in healthy Japanese, Caucasian and Korean subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans.
Jeong YS, Kim MS, Lee N, Lee A, et al · · 2021 · cited 19× · PMID 34072547 · DOI 10.3390/pharmaceutics13060813

Verify or expand the search:

Other trials of DWP14012

Trials testing the same drug.

NCT05812404 — Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects · Phase 1 · unknown
NCT05574374 — Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects · Phase 1 · completed
NCT05304845 — Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects · Phase 1 · completed
NCT05813561 — The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis · Phase 3 · completed
NCT04888819 — Treatment Effect According to Timing of Administration of DWP14012 40 mg · NA · unknown

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03574415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
Last refreshed: 27 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03574415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing